STOCK TITAN

NICE (NCSYF) HR executive reports multiple stock option grants to 2033

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

NICE Ltd. executive vice president of human resources Neder Shiri reported existing holdings of stock options on the company’s Ordinary Shares. The awards have exercise prices ranging from 0.2706 to 0.3228 and individual grants covering 1,200 to 12,500 underlying shares, with expirations between March 3, 2027 and February 18, 2033.

Footnotes explain that several options are already vested and exercisable, while others vest over future dates in 2027, 2028 and 2029. One performance-based grant is eligible to vest over a three-year performance period ending February 18, 2029, depending on specified stock price thresholds.

Positive

  • None.

Negative

  • None.
Insider Neder Shiri
Role EVP, Human Resources
Type Security Shares Price Value
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
Holdings After Transaction: Options — 1,800 shares (Direct)
Footnotes (1)
  1. The stock option is fully vested and currently exercisable. The stock option is vested and exercisable with respect to 6,862 Ordinary Shares and will vest with respect to the remaining shares on February 22, 2027. The stock option is vested and exercisable with respect to 4,575 Ordinary Shares and will vest with respect to the remaining shares in substantially equal installments on February 21, 2027 and February 21, 2028. The stock option is vested and exercisable with respect to 4,575 Ordinary Shares and will vest with respect to the remaining shares on February 22, 2027. The stock option is vested and exercisable with respect to 2,400 Ordinary Shares and will vest with respect to the remaining shares on June 1, 2027. The stock option is vested and exercisable with respect to 3,050 Ordinary Shares and will vest with respect to the remaining shares in substantially equal installments on February 21, 2027 and February 21, 2028. The stock option is vested and exercisable with respect to 2,500 Ordinary Shares and will vest with respect to the remaining shares in three substantially equal installments on February 19, 2027, February 19, 2028 and February 19, 2029. The stock option is vested and exercisable with respect to 1,600 Ordinary Shares and will vest with respect to the remaining shares on June 1, 2027. The stock option will vest in substantially equal installments on February 18, 2027, February 18, 2028, February 18, 2029 and February 18, 2030. The stock option is vested and exercisable with respect to 2,500 Ordinary Shares and will vest with respect to the remaining shares in substantially equal installments on February 19, 2027, February 19, 2028 and February 19, 2029 Each Option represents a contingent right to receive one Ordinary Share of the Issuer. The Options are eligible to vest over a three-year performance period ending February 18, 2029, subject to adjustments in accordance with the terms of the awards, based upon the Issuer?s achievement of specified stock price performance thresholds.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Neder Shiri

(Last)(First)(Middle)
221 RIVER STREET

(Street)
HOBOKEN NEW JERSEY 07030

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
NICE Ltd. [ NICE ]
3a. Foreign Trading Symbol
[NICE.TA]
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Human Resources
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options (1)03/03/2027Ordinary Shares1,800$0.307D
Options (1)02/16/2028Ordinary Shares3,750$0.3142D
Options (1)03/03/2028Ordinary Shares1,200$0.307D
Options (1)02/16/2029Ordinary Shares2,500$0.3142D
Options (2)02/22/2029Ordinary Shares9,150$0.273D
Options (3)02/21/2030Ordinary Shares9,150$0.2718D
Options (4)02/22/2030Ordinary Shares6,100$0.273D
Options (5)06/01/2030Ordinary Shares4,800$0.2706D
Options (6)02/21/2031Ordinary Shares6,100$0.2718D
Options (7)02/19/2031Ordinary Shares10,000$0.2824D
Options (8)06/01/2031Ordinary Shares3,200$0.2706D
Options (9)02/18/2032Ordinary Shares12,500$0.3228D
Options (10)02/19/2032Ordinary Shares10,000$0.2824D
Options (11)02/18/2033Ordinary Shares10,000$0.3228D
Explanation of Responses:
1. The stock option is fully vested and currently exercisable.
2. The stock option is vested and exercisable with respect to 6,862 Ordinary Shares and will vest with respect to the remaining shares on February 22, 2027.
3. The stock option is vested and exercisable with respect to 4,575 Ordinary Shares and will vest with respect to the remaining shares in substantially equal installments on February 21, 2027 and February 21, 2028.
4. The stock option is vested and exercisable with respect to 4,575 Ordinary Shares and will vest with respect to the remaining shares on February 22, 2027.
5. The stock option is vested and exercisable with respect to 2,400 Ordinary Shares and will vest with respect to the remaining shares on June 1, 2027.
6. The stock option is vested and exercisable with respect to 3,050 Ordinary Shares and will vest with respect to the remaining shares in substantially equal installments on February 21, 2027 and February 21, 2028.
7. The stock option is vested and exercisable with respect to 2,500 Ordinary Shares and will vest with respect to the remaining shares in three substantially equal installments on February 19, 2027, February 19, 2028 and February 19, 2029.
8. The stock option is vested and exercisable with respect to 1,600 Ordinary Shares and will vest with respect to the remaining shares on June 1, 2027.
9. The stock option will vest in substantially equal installments on February 18, 2027, February 18, 2028, February 18, 2029 and February 18, 2030.
10. The stock option is vested and exercisable with respect to 2,500 Ordinary Shares and will vest with respect to the remaining shares in substantially equal installments on February 19, 2027, February 19, 2028 and February 19, 2029
11. Each Option represents a contingent right to receive one Ordinary Share of the Issuer. The Options are eligible to vest over a three-year performance period ending February 18, 2029, subject to adjustments in accordance with the terms of the awards, based upon the Issuer?s achievement of specified stock price performance thresholds.
Remarks:
Exhibit 24 - Power of Attorney.
/s/ Alon Levy, Attorney-in-Fact for Shiri Neder03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the NICE (NCSYF) Form 3 filing report for Neder Shiri?

The filing reports Neder Shiri’s existing stock option holdings in NICE Ltd. Ordinary Shares. It lists multiple option grants, their exercise prices, expiration dates through 2033, and detailed vesting schedules, including which portions are already exercisable and which will vest in future years.

What are the key expiration dates of Neder Shiri’s NICE stock options?

Shiri’s reported stock options expire on various dates from March 3, 2027 through February 18, 2033. Each grant has its own specific expiration date, reflecting a staggered schedule that extends over several years of potential exercisability if vesting and other conditions are satisfied.

How much of Neder Shiri’s NICE option grants are already vested?

Several grants are described as vested and currently exercisable with specific underlying share amounts, such as 6,862 and 4,575 shares in different awards. The remaining portions of those grants are scheduled to vest on future dates, mainly in 2027 and 2028, subject to continued eligibility.

Does Neder Shiri hold performance-based NICE stock options?

Yes. One option grant vests over a three-year performance period ending February 18, 2029. Vesting depends on NICE’s achievement of specified stock price performance thresholds, and each option represents a contingent right to receive one Ordinary Share if those conditions are met.

What exercise prices are disclosed for Neder Shiri’s NICE options?

The disclosed exercise prices for Shiri’s options range from 0.2706 to 0.3228 per share. Each option series has a specific exercise price, tied to its grant, and the filing lists these alongside the corresponding expiration dates and the number of underlying Ordinary Shares.

Are all of Neder Shiri’s NICE options time-based, or are some performance-based?

The filing shows both time-based and performance-based vesting. Several options vest on specified calendar dates or in substantially equal installments across 2027–2029, while one grant vests over a performance period ending February 18, 2029, based on stock price performance thresholds.